Last reviewed · How we verify
Adapalene 0.1% gel plus clindamycin 1% gel — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Adapalene 0.1% gel plus clindamycin 1% gel (Adapalene 0.1% gel plus clindamycin 1% gel) — All India Institute of Medical Sciences, Bhubaneswar.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Adapalene 0.1% gel plus clindamycin 1% gel TARGET | Adapalene 0.1% gel plus clindamycin 1% gel | All India Institute of Medical Sciences, Bhubaneswar | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Adapalene 0.1% gel plus clindamycin 1% gel CI watch — RSS
- Adapalene 0.1% gel plus clindamycin 1% gel CI watch — Atom
- Adapalene 0.1% gel plus clindamycin 1% gel CI watch — JSON
- Adapalene 0.1% gel plus clindamycin 1% gel alone — RSS
Cite this brief
Drug Landscape (2026). Adapalene 0.1% gel plus clindamycin 1% gel — Competitive Intelligence Brief. https://druglandscape.com/ci/adapalene-0-1-gel-plus-clindamycin-1-gel. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab